Patient has an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 14 days prior to planned first dose of study drug
Active infection requiring within 2 weeks prior to first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before enrollment; active infection requiring systemic therapy
Serious, systemic infection requiring treatment ? 7 days before the first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug.
Serious, systemic infection requiring treatment =< 7 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before enrollment
Recent culture-documented infection requiring intravenous antimicrobials that was completed =< 7 days before the first dose of study drug or any uncontrolled active systemic infection; fever of unknown origin is not an exclusion criterion, as this may be disease-related
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed
Patient has an active systemic infection requiring treatment or within 14 days before first dose of PRLX 93936.
Recent culture-documented infection requiring systemic intravenous treatment that was completed =< 7 days before the first dose of study drug or any uncontrolled active systemic infection; fever of unknown origin is not an exclusion criterion, as this may be disease-related
Active infection requiring treatment ? 7 days before first dose of study drug
Has an active infection or recent history (<30 days before study drug administration) requiring systemic treatment
Recent infection requiring systemic treatment that was completed =< 14 days before starting treatment on the study
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Active infection requiring treatment ?7 days before the first dose of study drug
Recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug
Active infection at initiation of study; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring systemic treatment within 7 days prior to the first dose of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 7 days prior to the first dose of study drug.
Any uncontrolled active systemic infection or recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Subject has evidence of an active infection requiring systemic therapy within 14 days prior to the planned first dose of study drug.
Subject has evidence of active infection requiring systemic therapy within 14 days prior to the first dose of study drug.
Recent infection requiring intravenous (IV) systemic treatment that was completed ?14 days before the first dose of study drug.
Patient with an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 4 days prior to planned initial dose of WT2725.
Serious infection within 14 days before the first dose of study drug. Participant must have recovered from infection before first dose.
Recent infection requiring IV anti-infective treatment that was completed ?14 days before the first dose of study drug
Recent infection requiring intravenous systemic treatment that was completed =< 14 days before the first dose of study drug or any uncontrolled active systemic infection
Recent infection requiring systemic treatment that was completed =< 7 days before the first dose of study drug
Active infection requiring within 2 weeks prior to first dose of study drug
